ANO1 and prostate carcinoma: Recent evidence suggests that pharmacological inhibition of ANO1 may have beneficial effects on HNSCC, esophageal squamous cell carcinoma (ESCC), gastrointestinal stromal tumours (GIST), breast and prostate cancer [5, 15, 16].